Oral mucositis (ulcerative) due to antineoplastic therapy. 2016 2017 2018 2019 Billable/Specific Code. K12.31 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM K12.31 became effective on October 1, 2018.
| ICD-10 from 2011 - 2016 K12.31 is a billable ICD code used to specify a diagnosis of oral mucositis (ulcerative) due to antineoplastic therapy. A 'billable code' is detailed enough to be used to specify a medical diagnosis. The ICD code K12 is used to code Mouth ulcer
ICD-10 code Z51.11 for Encounter for antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services . Subscribe to Codify and get the code details in a flash.
1 for Encounter for antineoplastic chemotherapy and immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Antineoplastic chemotherapy drugs are a type of medication that doctors use to treat cancer. They contain chemicals that kill cells that rapidly divide, including cancer cells.
ICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
Z51. 11 is attached to the billing for the administration of chemotherapy so would not be used by the provider when the patient is going to a hospital-owned infusion center.
Antineoplastic drugs, also known as chemotherapy, cytotoxic and oncology drugs, are used to treat cancer, as well as arthritis, multiple sclerosis, and other non-cancer medical conditions. Most antineoplastic drugs are classified by NIOSH as hazardous drugs.
Listen to pronunciation. (AN-tee-NEE-oh-PLAS-tik) Blocking the formation of neoplasms (growths that may become cancer).
Gastrointestinal mucositis (ulcerative) K92. 81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM K92. 81 became effective on October 1, 2021.
1X5 for Adverse effect of antineoplastic and immunosuppressive drugs is a medical classification as listed by WHO under the range - Injury, poisoning and certain other consequences of external causes .
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug (T36-T50).
ICD-10 code Z51. 81 for Encounter for therapeutic drug level monitoring is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
ICD-10 code: C90. 00 Multiple myeloma Without mention of complete remission.
11, Encounter for antineoplastic chemotherapy; or Z51.
Many of the medications used to manage the most common toxicities of antineoplastic therapies further alter body functions and can perpetuate a decline in functioning. One of the most common side effects of many antineoplastic drugs therapies is nausea/vomiting (N/V).
Overview. Antineoplastic drugs, also known as chemotherapy, cytotoxic and oncology drugs, are used to treat cancer, as well as arthritis, multiple sclerosis, and other non-cancer medical conditions. Most antineoplastic drugs are classified by NIOSH as hazardous drugs.
Antineoplastic agents that are well known to cause significant direct hepatotoxicity when given in moderate to high doses (particularly when used in myeloablation before hematopoietic cell transplantation) include busulfan, melphalan, cyclophosphamide, dacarbazine, cytarabine, fluorouracil, carboplatin and L- ...
The exposure of health care workers to antineoplastic drugs is associated with several adverse health effects, including reproductive toxicities and mutagenic effects. Recent studies have confirmed that Canadian health care workers are at risk of exposure to these agents.
Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Symptoms can include pain, vomiting and diarrhoea, which can often necessitate chemotherapy treatment breaks or dose reductions, thus compromising survival outcomes. Despite the significant impact of …
Free, official coding info for 2022 ICD-10-CM K12.32 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
Approximate Synonyms. Oral mucositis; ICD-10-CM K12.30 is grouped within Diagnostic Related Group(s) (MS-DRG v 39.0):. 011 Tracheostomy for face, mouth and neck diagnoses or laryngectomy with mcc; 012 Tracheostomy for face, mouth and neck diagnoses or laryngectomy with cc; 013 Tracheostomy for face, mouth and neck diagnoses or laryngectomy without cc/mcc
K12.31 is a billable diagnosis code used to specify a medical diagnosis of oral mucositis (ulcerative) due to antineoplastic therapy. The code K12.31 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
Dry mouth - a lack of enough saliva, caused by some medicines and certain diseases
code for adverse effect, if applicable, to identify antineoplastic and immunosuppressive drugs T45.1X5
Use Additional Code. Use Additional Code. The “use additional code” indicates that a secondary code could be used to further specify the patient’s condition. This note is not mandatory and is only used if enough information is available to assign an additional code.
A mouth ulcer (also termed an oral ulcer, or a mucosal ulcer) is an ulcer that occurs on the mucous membrane of the oral cavity. Mouth ulcers are very common, occurring in association with many diseases and by many different mechanisms, but usually there is no serious underlying cause.
Use Additional Code note means a second code must be used in conjunction with this code. Codes with this note are Etiology codes and must be followed by a Manifestation code or codes.
This means that while there is no exact mapping between this ICD10 code K12.31 and a single ICD9 code, 528.01 is an approximate match for comparison and conversion purposes.
The 2022 edition of ICD-10-CM K12.32 became effective on October 1, 2021.
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
The 2022 edition of ICD-10-CM K12.31 became effective on October 1, 2021.